Abstract Background The BCR::ABL1 tyrosine kinase inhibitors (TKIs) have significantly improved the outcomes of patients with Philadelphia chromosome (Ph)-positive acute lymphoblastic leukemia (ALL). However, the optimal duration of TKI therapy in patients who achieve a complete molecular response (CMR; undetectable BCR::ABL1 transcripts) and who do not undergo allogeneic stem cell transplantation (allo-SCT) remains undefined. Methods… Continue reading Treatment‐free remission in nontransplanted patients with Philadelphia chromosome‐positive acute lymphoblastic leukemia
Tag: Leukemia and Lymphoma
Can Knowledge From Treating Chronic Myeloid Leukemia Inform Therapy of EGFR -Mutant Lung Adenocarcinoma?
This Viewpoint discusses how therapy of chronic myeloid leukemia can inform therapy of lung cancer.
[ASAP] Design, Synthesis, and Biological Evaluation of Novel Fms-Like Tyrosine Kinase 3/VEGFR2/Histone Deacetylase Inhibitors for the Treatment of Acute Myeloid Leukemia
Outcome correlates of approved CD19-targeted CAR T cells for large B cell lymphoma
Abstract CD19-targeted chimeric antigen receptor (CAR) T cells have provided a breakthrough in the treatment of patients with relapsed and/or refractory large B cell lymphoma (LBCL). Currently, three CD19-targeted CAR T cell products are approved by the FDA and various other regulators for the treatment of patients with LBCL: axicabtagene ciloleucel, tisagenlecleucel and lisocabtagene maraleucel.… Continue reading Outcome correlates of approved CD19-targeted CAR T cells for large B cell lymphoma
Reply to the Letter to the Editor ‘Comments on the study of correlation between progression-free and overall survival in patients with Hodgkin lymphoma’ by Zeng et al.
We would like to thank Drs Zeng and colleagues for their interest1 in our comprehensive analysis of individual data from >10 000 patients showing a strong correlation between progression-free survival (PFS) and overall survival (OS) after 26 different types of first-line treatment within nine randomized, international academic trials.2
Blinatumomab Boosts Chemotherapy as Initial Treatment for Some Kids with ALL
Following positive results from a clinical trial, the immunotherapy drug blinatumomab (Blincyto) is expected to become part of the standard initial treatment for many kids with B-cell acute lymphoblastic leukemia, the most common form of childhood cancer.
Maintenance therapy with the FMS‐like tyrosine kinase 3 inhibitor gilteritinib in patients with FMS‐like tyrosine kinase 3–internal tandem duplication acute myeloid leukemia: A phase 2 study
Abstract Background The GOSSAMER phase 2 study assessed the FMS-like tyrosine kinase 3 (FLT3) inhibitor gilteritinib as maintenance therapy in patients with FLT3–internal tandem duplication (FLT3-ITD) acute myeloid leukemia (AML) in first complete remission without previous hematopoietic stem cell transplantation (HSCT). Methods Patients had to be within 2 months of their last consolidation cycle and… Continue reading Maintenance therapy with the FMS‐like tyrosine kinase 3 inhibitor gilteritinib in patients with FMS‐like tyrosine kinase 3–internal tandem duplication acute myeloid leukemia: A phase 2 study
Maintenance therapy with the FMS‐like tyrosine kinase 3 inhibitor gilteritinib in patients with FMS‐like tyrosine kinase 3–internal tandem duplication acute myeloid leukemia: A phase 2 study
Abstract Background The GOSSAMER phase 2 study assessed the FMS-like tyrosine kinase 3 (FLT3) inhibitor gilteritinib as maintenance therapy in patients with FLT3–internal tandem duplication (FLT3-ITD) acute myeloid leukemia (AML) in first complete remission without previous hematopoietic stem cell transplantation (HSCT). Methods Patients had to be within 2 months of their last consolidation cycle and… Continue reading Maintenance therapy with the FMS‐like tyrosine kinase 3 inhibitor gilteritinib in patients with FMS‐like tyrosine kinase 3–internal tandem duplication acute myeloid leukemia: A phase 2 study